Adamas Pharma (ADMS) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
February 23, 2021 4:03 PM ESTFourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019
Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019
Second indication received February 2021 for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinsons disease patients experiencing OFF episodes
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended... More
